Background Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an adeno-associated virus 5
(AAV5)–based gene-therapy vector containing a coagulation factor VIII complementary DNA …

Introduction The World Federation of Hemophilia (WFH) strives to achieve care for all
patients with inherited bleeding disorders through research, advocacy, capacity building and …

Background Gene therapy trial results show potential to cure haemophilia A and haemophilia
B. Securing broad access to a cure for a lifelong chronic disease is anticipated to face …

Historically, treatment based on the availability of clotting factor replacement has resulted in
an arcane guideline for the correction of factor deficiencies in people with haemophilia (PwH…

Gene therapy has the potential to revolutionise treatment for patients with haemophilia and
is close to entering clinical practice. While factor concentrates have improved outcomes, …

The World Federation of Haemophilia (WFH) estimates that worldwide, approximately 70%
of patients with hemophilia are underdiagnosed and untreated. Most live in developing …

Introduction The COVID‐19 pandemic caused an unprecedented impact to haemophilia
healthcare delivery. In particular, rapid implementation of telehealth solutions was required to …

A questionnaire was circulated in 2012 to national haemophilia patient organizations in Europe
affiliated to the European Haemophilia Consortium ( EHC ) and the World Federation of …

Background In spite of recent major advances in the understanding and treatment of inhibitor
development in patients with haemophilia, multidisciplinary management of many of these …

The introduction of adeno-associated virus–mediated, liver-directed gene therapy into the
hemophilia treatment landscape brings not only great promise but also considerable …